Once versus twice daily direct oral anticoagulants in patients with recent stroke and atrial fibrillation.

Publikation

Once versus twice daily direct oral anticoagulants in patients with recent stroke and atrial fibrillation.

Wissenschaftlicher Artikel/Review - 10.05.2022

Polymeris Alexandros A, Zietz Annaelle, Schaub Fabian, Meya Louisa, Traenka Christopher, Thilemann Sebastian, Wagner Benjamin, Hert Lisa, Altersberger Valerian L, Seiffge David Julian, Lyrer Flurina, Dittrich Tolga, Piot Ines, Kaufmann Josefin, Barone Lea, Dahlheim Ludvig, Flammer Sophie, Avramiotis Nikolaos S, Peters Nils, De Marchis Gian Marco, Bonati Leo H, Gensicke Henrik, Engelter Stefan T, Lyrer Philippe A

Zitation

Polymeris A, Zietz A, Schaub F, Meya L, Traenka C, Thilemann S, Wagner B, Hert L, Altersberger V, Seiffge D, Lyrer F, Dittrich T, Piot I, Kaufmann J, Barone L, Dahlheim L, Flammer S, Avramiotis N, Peters N, De Marchis G, Bonati L, Gensicke H, Engelter S, Lyrer P. Once versus twice daily direct oral anticoagulants in patients with recent stroke and atrial fibrillation. Eur Stroke J 2022; 7:221-229.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Eur Stroke J 2022; 7

Veröffentlichungsdatum

10.05.2022

eISSN (Online)

2396-9881

Seiten

221-229

Kurzbeschreibung/Zielsetzung

Data on the safety and effectiveness of once-daily (QD) versus twice-daily (BID) direct oral anticoagulants (DOAC) in comparison to vitamin K antagonists (VKA) and to one another in patients with atrial fibrillation (AF) and recent stroke are scarce.